LENZ THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.79 USD | +14.18% |
|
+17.97% | 0.00% |
| Apr. 15 | Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target | MT |
| Apr. 15 | William Blair Starts LENZ Therapeutics With Outperform Rating | MT |
Evolution of the average Target Price on LENZ Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
e5173e.hfZG8rGLepTAXq-lvDGfZ-scnuTj8XxWcMjBF4V_FxA.yoMvkIn8I9CXaeX17mDcPpJQ-qWJgBoCOLGvVuk1JiPRoBeE-_w57PYxmw~64949bb868282b34584861c69ba4e0eb
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.79
USD
Average target price
35.6
USD
Spread / Average Target
+100.11%
High Price Target
45
USD
Spread / Highest target
+152.95%
Low Price Target
31
USD
Spread / Lowest Target
+74.26%
Consensus detail
Consensus revision (last 18 months)
Analysts covering LENZ Therapeutics, Inc.
| Leerink Partners | |
| William Blair & Co. | |
| Piper Sandler |
EPS Revisions
- Stock Market
- Equities
- LENZ Stock
- Consensus LENZ Therapeutics, Inc.
